The Safety, Tolerability, and Efficacy of KD01 in Gynecologic Malignancies

NCT06552598 | Recruiting Phase 1

• 1 other identifier: 2024-TJ-KD01
• Study Type: interventional
• Target: 97
• Locations: 1 country
• Sites: 1

Brief Summary

Recombinant oncolytic adenovirus injection (KD01)is an oncolytic vius product. Its main component is a conditionally replicativerecombinant human type 5 adenovirus, where part of the E3 region has been replaced with the gene encoding the tBid apoptoticprotein.AK104 is a humanized bispecific antibody co-targeting PD-1 (Programmed Cell Death Protein 1) and CTLA-4 (Cytotoxic T-Lymphocyte-Associated Antigen 4)-two key immune checkpoint receptors. It is designed as a novel tetrameric construct that preferentially binds to tumor-infiltrating lymphocytes (TILs) co-expressing PD-1 and CTLA-4 in the tumor microenvironment (withhigher avidity than in peripheral tissues).This study aims to investigate the therapeutic efficacy and safety of recombinant oncolytic adenovirus (KD01) in patients with gynecologic malignancies. Meanwhile, it will explore the impact of KD01 on the immune function of cervical cancer patients as well as its tumor cell-killing mechanism. This research is expected to provide novel strategies and approaches for the treatment of gynecologic malignancies, and contribute to improving the rehabilitation and quality of life of patients. The study is divided into Phase I and Phase II. Phase II consists of Cohort A (cervical cancer cohort) and Cohort B (endometrial cancer cohort).Phase I will include patients with gynecologic malignancies who have failed systemic therapy.Phase II will include reproductive-aged women with a strong desire to preserve fertility.Phase II Cohort A will include patients with cervical squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma, staged as IB1 (tumor size ≥1 cm), IB2, IB3 (tumor size ≤5 cm) and IIA1 (based on FIGO 2018 staging system); baseline MRI examination confirms that the lesion does not involve the lower uterine segment; for patients in Stage II , the length of vaginal involvement is \< 2 cm.Phase II Cohort B will include patients with endometrial atypical hyperplasia or endometrial adenocarcinoma (FIGO Grade 1-Grade 2, FIGO 2023 Stage IA1 and IA2), with mismatch repair deficiency (MMRd) or no response to progestogen therapy; baseline MRI examination combined with chest CT or PET/CT confirms that the lesion is limited to the endometrial layer or superficial myometrium, without obvious involvement of the deep myometrium, cervix or extrauterine sites.

Conditions

Cervical Cancer; Gynecologic Malignancies; Endometrial Cancer

Outcome Measures

Primary Outcomes (4)

• SAEs and AEs in Phase I

  Incidence of serious adverse events (SAEs), incidence and severity of adverse events (AEs).

  2 years

• MTD and RD in Phase I

  Determine the maximum tolerated dose (MTD) based on the incidence of dose-limiting toxicities (DLTs), and derive the recommended dose (RD) for monotherapy.

  2 years

• ORR in Phase II Cohort A

  Objective response rate (ORR) following neoadjuvant therapy (preoperative treatment).

  2 years

• CR in Phase II Cohort B

  Complete response (CR) rate at 6 months.

  6 months

Secondary Outcomes (5)

• Biodistribution in Phase I

  2 years

• RFS in Phase II

  2 years

• pCR in Phase II Cohort A

  2 years

• Disease response rate in Phase II Cohort B

  12 months

• SAEs and AEs in Phase II

  2 years

Other Outcomes (2)

• Anti-Ad5 adenovirus antibody

  2 years

• Immunogenicity

  2 years

Study Arms (1)

KD01 treatment

EXPERIMENTAL

Local administration of Recombinant Oncolytic Adenovirus Injection (KD01) in gynecologic malignancies.

Drug: KD01(the recombinant oncolytic adenovirus)

Interventions

KD01(the recombinant oncolytic adenovirus) DRUG

Drug: Phase I: KD01(1×10¹¹ VP, 1×10¹¹ VP, and 6×10¹¹ VP) Phase II Cohort A: KD01(3×10¹¹ VP)+AK104(6 mg/kg)+thymalfasin + rhGM-CSF Phase II Cohort B: KD01(1×10¹¹ VP) + LNG-IUS Administration： Phase I: KD01 will be administered of Cycle 1 (Days 1-5). And subsequent cycles will be repeated every 26 + 7 days thereafter. Phase II Cohort A: KD01 will be administered daily on Days 1-5).AK104will be administered on Day 14.KD01 will be resumed daily for up to 5 doses.A second dose of AK104 will be administered on Day 28.Concurrent administration of thymalfasin and rhGM-CSF.Efficacy assessment will be performed on Day 42 . The first elective surgery will be scheduled after evaluation by the investigator. Phase II Cohort B: Hysteroscopy will be performed on Day 1; subsequently, KD01 will be administered, and a LNG-IUS will be placed. Thereafter, hysteroscopic diagnostic curettage/biopsy will be carried out every 3 months, accompanied by administration of KD01 and placement of LNG-IUS.

KD01 treatment

Eligibility Criteria

• Age: 18 Years+
• Gender Eligibility Details: Patients with cervical malignancies
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Phase II: Reproductive-aged women with a strong desire to preserve fertility, who understand and accept potential risks (recommended age ≤ 40 years old).Cohort A (Cervical Cancer Cohort): Histologically confirmed cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma, staged as IB1 (tumor size ≥ 1 cm), IB2, IB3 (tumor size ≤ 5 cm), or IIA1 (FIGO 2018 ). Baseline MRI confirms no involvement of the lower uterine segment; vaginal involvement length \< 2 cm for Stage II patients.Cohort B (Endometrial Cancer Cohort): Histologically confirmed endometrial atypical hyperplasia or endometrial adenocarcinoma (FIGO Grade 1-Grade 2, FIGO 2023 Stage IA1 and IA2), with mismatch repair deficiency (MMRd) or no response to progestogen therapy. Baseline MRI combined with chest CT or PET/CT confirms lesions are limited to the endometrial layer or superficial myometrium, with no obvious involvement of the deep myometrium, cervix, or extrauterine sites.
• Eastern Cooperative Oncology Group (ECOG) Performance Status: 0 or 1.
• Expected Survival: ≥ 3 months.
• No major organ dysfunction, including but not limited to hematopoietic, cardiac, pulmonary, hepatic, and renal function.
• Hematological system ( no blood transfusion or hematopoietic stimulant therapy administered within 14 days prior to screening)：
• Absolute Neutrophil Count (ANC)≥ 1.5 × 10⁹/L
• Platelet Count (PLT)≥ 75 × 10⁹/L
• Hemoglobin (Hb)≥ 90 g/L Hepatic System：
• a.Total Bilirubin (TBIL)≤ 1.5 × Upper Limit of Normal (ULN) b.Alanine Aminotransferase (ALT)≤ 3 × ULN; ≤ 5 × ULN for patients with liver metastases or primary liver cancer c.Aspartate Aminotransferase (AST)≤ 3 × ULN; ≤ 5 × ULN for patients with liver metastases or primary liver cancer
• Renal System:
• Creatinine (Cr)≤ 1.5 × ULN
• Creatinine Clearance (Ccr) (calculated only if Cr \> 1.5 × ULN)\> 50 mL/min (per Cockcroft-Gault formula)
• Coagulation System:
• Activated Partial Thromboplastin Time (APTT)≤ 1.5 × ULN
• International Normalized Ratio (INR)≤ 1.5 × ULN

You may not qualify if:

• History of Severe Cardiovascular and Cerebrovascular Diseases, including but not limited to:
• Severe cardiac rhythm or conduction abnormalities requiring clinical intervention (e.g., symptomatic ventricular arrhythmias, Grade II-III atrioventricular block);
• Corrected QT interval (QTcF) ≥ 460 ms on 12-lead electrocardiogram at rest;
• Acute coronary syndrome, congestive heart failure, aortic dissection, stroke, or other Grade ≥ 3 cardiovascular events within 6 months prior to the first dose;
• New York Heart Association (NYHA) Functional Class ≥ II, left ventricular ejection fraction (LVEF) \< 50%, or other structural heart diseases deemed high-risk by the investigator;
• Clinically uncontrolled hypertension.
• Phase II: Imaging evidence of significant retroperitoneal lymph node metastasis;Cohort A (Cervical Cancer Cohort): Imaging evidence of lower uterine segment or endometrial involvement; Cohort B (Endometrial Cancer Cohort): Imaging evidence of deep myometrial, cervical, or extrauterine tumor invasion.
• Clinically significant serous effusion requiring intervention within 4 weeks prior to informed consent.
• History of autoimmune disease, immune system dysfunction, or organ transplantation.
• Active infection requiring systemic anti-infective therapy (routine prophylactic anti-infective therapy per clinical trial institution is excluded); or unexplained fever \> 38.5°C during screening.
• Positive results for human immunodeficiency virus antibody (HIV-Ab) or treponema pallidum antibody; active hepatitis B (hepatitis B surface antigen \[HBsAg\] positive with HBV-DNA \> 500 IU/mL or above the lower limit of detection of the clinical trial institution, if the lower limit is higher than 500 IU/mL); active hepatitis C (patients with positive HCV antibody but undetectable HCV-RNA are eligible). Patients receiving prophylactic antiviral therapy (excluding interferon) are eligible.
• Uncontrolled seizures, central nervous system disorders, or psychiatric conditions resulting in cognitive impairment.
• Adverse reactions from prior anti-tumor therapy have not resolved to grade ≤ 1 (per the Common Terminology Criteria for Adverse Events (CTCAE) v5.0), with the exception of toxicities judged by the investigator to pose no safety risks (e.g., alopecia).
• Current requirement for antiviral therapy, or use of antiviral drugs within 2 weeks prior to the first dose of study drug.
• Receipt of nitrosourea or mitomycin C within 6 weeks prior to the first dose;Receipt of oral fluoropyrimidines or small-molecule targeted agents within 2 weeks prior to the first dose or within 5 half-lives of the drug (whichever is longer);Receipt of traditional Chinese medicine with anti-tumor indications within 2 weeks prior to the first dose;Receipt of other chemotherapy, radiotherapy, biological therapy, endocrine therapy (excluding progestogen use in Phase II Cohort B), immunotherapy, etc., within 4 weeks prior to the first dose.

Sponsors & Collaborators

• Tongji Hospital: lead

Study Sites (1)

Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430030, China

RECRUITING

MeSH Terms

Conditions

Uterine Cervical Neoplasms; Endometrial Neoplasms

Condition Hierarchy (Ancestors)

Uterine Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Uterine Cervical Diseases; Uterine Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases

Central Study Contacts

Qinglei Gao, PhD

CONTACT

15391566981; qingleigao@hotmail.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: August 11, 2024
• First Posted: August 14, 2024
• Study Start: April 1, 2024
• Primary Completion (Estimated): April 1, 2028
• Study Completion (Estimated): April 1, 2028
• Last Updated: January 15, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)